Compounds > abi-274
Page last updated: 2024-11-13

abi-274

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ABI-274: a tubulin inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID49787837
CHEMBL ID1272023
SCHEMBL ID724651
MeSH IDM000598407

Synonyms (15)

Synonym
CHEMBL1272023
SCHEMBL724651
NQHVDNDKHQBFKP-UHFFFAOYSA-N
(2-(p-tolyl)-1h-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone
2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzoyl)-1h-imidazole
AS-71246
[2-(4-methylphenyl)-1h-imidazol-5-yl]-(3,4,5-trimethoxyphenyl)methanone
(2-p-tolyl-1h-imidazol-5-yl)(3,4,5-trimethoxyphenyl)methanone
1253697-93-6
(2-(p-tolyl)-1h-imidazol-5-yl)(3,4,5-trimethoxyphenyl)methanone
[2-(4-methylphenyl)-1h-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone
o91 ,
D86736
abi-274
AKOS037646856
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID612334Half life in mouse liver microsomes at 0.5 uM by LC-MS analysis2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
AID729108Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.
AID526951Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID526952Cytotoxicity against human PPC1 cells after 48 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID526949Cytotoxicity against human LNCAP cells after 48 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID526946Cytotoxicity against human A375 cells after 48 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID729161Cytotoxicity against human MDA-MB-435/LCC6MDR1 cells assessed as growth inhibition after 48 hrs by SRB assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.
AID729103Cytotoxicity against human LNCAP cells assessed as growth inhibition after 96 hrs by SRB assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.
AID526950Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID1582210Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTS assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
AID612335Half life in rat liver microsomes at 0.5 uM by LC-MS analysis2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
AID1582214Antiproliferative activity against human M14 cells measured after 72 hrs by MTS assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
AID612338Inhibition of bovine brain tubulin polymerization after 15 mins by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
AID729106Cytotoxicity against human DU145 cells assessed as growth inhibition after 96 hrs by SRB assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.
AID729107Cytotoxicity against human A375 cells assessed as growth inhibition after 48 hrs by SRB assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.
AID729105Cytotoxicity against human PPC1 cells assessed as growth inhibition after 96 hrs by SRB assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.
AID729104Cytotoxicity against human PC3 cells assessed as growth inhibition after 96 hrs by SRB assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.
AID612336Metabolic stability of the compound in dog liver microsomes at 0.5 uM up to 90 mins by LC-MS analysis2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
AID612331Metabolic stability of the compound in human liver microsomes at 50 uM up to 90 mins by LC-MS analysis2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
AID1582213Antiproliferative activity against human A375 cells measured after 72 hrs by MTS assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
AID1582212Antiproliferative activity against human SK-BR-3 cells measured after 72 hrs by MTS assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
AID612330Metabolic stability of the compound in human liver microsomes at 0.5 uM up to 90 mins by LC-MS analysis2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.
AID1582211Antiproliferative activity against human MDA-MB-453 cells measured after 72 hrs by MTS assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
AID526948Cytotoxicity against human WM164 cells after 48 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID526947Cytotoxicity against mouse B16-F1 cells after 48 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID526942Inhibition of bovine brain tubulin polymerization at 10 uM after 15 mins2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID1582215Antiproliferative activity against human RPMI7951 cells measured after 72 hrs by MTS assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
AID1582225Inhibition of porcine brain tubulin polymerization at 10 uM measured at 30 secs interval for 65 mins by spectrophotometric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.28 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		3.0140alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
vinblastine
[no description available]		2.4720
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		3.0140taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
fosbretabulin
[no description available]		2.0510stilbenoid
plx4032
[no description available]		2.110aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.0510dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.2510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.2510
Malignant Melanoma
[description not available]		02.110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		07.110